SNOA

Sonoma Pharmaceuticals, Inc. [SNOA] Stock Forecast

Q: What is Sonoma Pharmaceuticals, Inc. stock symbol ?

Sonoma Pharmaceuticals, Inc. is a US stock, located in Woodstock of Ga and trading under the symbol SNOA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SNOA Stock Summary

Earnings have grown 5.1% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 49.27%

Earnings are expected to fall -100% next year

Does not have any significance market cap ($4.01M)

Profit margins (-0.45%) are lower than the previous year (-0.39%)

Top 10 Correlated ETFs

SNOA

Top 10 Correlated Stocks

SNOA

In the News

05:05 29 Sep 2023 SNOA

Sonoma Pharmaceuticals Shares Soar 44% After Introducing New Product

Sonoma Pharmaceuticals shares jumped 44% on Friday after the company unveiled a product that could replace IV bags for some surgeries.

04:40 29 Sep 2023 SNOA

Markets End the Week in the Green in Anticipation the Fed Will Pause Rate Hikes

Markets posted a winning day on Friday, June 9, 2023, to top off a winning week on optimism the Fed may pause its interest rate hike cycle next week.

10:02 29 Sep 2023 SNOA

5 Penny Stocks To Watch With Big News This Week

Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:30 29 Sep 2023 SNOA

7 Top Penny Stocks To Watch With Big News This Week

Penny Stocks With News Light Up The Scanners This Week This week

06:00 29 Sep 2023 SNOA

Why Investing in Penny Stocks Could Be Worth It

Are penny stocks worth investing in? The post Why Investing in Penny Stocks Could Be Worth It appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:23 29 Sep 2023 SNOA

Why Is Sonoma Pharmaceuticals (SNOA) Up 70% Today?

Sonoma Pharmaceuticals (NASDAQ: SNOA ) stock is rocketing higher on Wednesday following positive news for its Microcyn Rx products. The big news here is Sonoma Pharmaceuticals getting a Distribution and Pricing Agreement (DAPA) from the Defense Logistics Agency ( DLA ).

06:00 29 Sep 2023 SNOA

What Makes Penny Stocks an Attractive Investment?

Are penny stocks on your watchlist right now? The post What Makes Penny Stocks an Attractive Investment?

01:13 29 Sep 2023 SNOA

Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?

Sonoma Pharmaceuticals (SNOA) stock is getting a boost on Tuesday after the company revealed positive disinfectant news from the EPA. The post Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?

09:33 29 Sep 2023 SNOA

Best Penny Stocks to Buy Today? 3 to Watch on May 3rd

What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

01:41 29 Sep 2023 SNOA

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

SNOA Financial details

Company Rating

Neutral

Market Cap

4.01M

Income

-5.68M

Revenue

12.72M

Book val./share

1.47

Cash/share

0.72

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

13 Nov 2023

P/E

-0.68

Forward P/E

PEG

0.45

P/S

0.32

P/B

0.53

P/C

1.08

P/FCF

-0.79

Quick Ratio

1.48

Current Ratio

3.36

Debt / Equity

0.09

LT Debt / Equity

0.02

EPS (TTM)

-1.63

EPS next Y

EPS next Q

EPS this Y

-20.83%

EPS next Y

EPS next 5Y

EPS last 5Y

-34.67%

Revenue last 5Y

-6.89%

Revenue Q/Q

13.7%

EPS Q/Q

-25.64%

SMA20

SMA50

SMA100

Inst Own

4.77%

Inst Trans

1.01%

ROA

-36%

ROE

-82%

ROC

-0.42%

Gross Margin

33%

Oper. Margin

-39%

Profit Margin

-45%

Payout

Shs Outstand

5.18M

Shs Float

4.89M

Target Price

52W Range

0.755-3.34

52W High

52W Low

RSI

Rel Volume

3.05

Avg Volume

24.3K

Volume

74K

Perf Week

2.24%

Perf Month

-8.59%

Perf Quarter

-19.06%

Perf Half Y

-32.43%

Beta

1.22925

Volatility

0.01%, 0.08%

Prev Close

-0.38%

Price

0.777

Change

-2.88%

SNOA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31
Revenue per share	20.53	12.82	9.33	4.76	3.91
Net income per share	-12.77	-1.99	-2.31	-1.92	-1.52
Operating cash flow per share	-12.68	-3.11	-1.69	-1.6	-1.81
Free cash flow per share	-12.79	-3.25	-1.78	-1.65	-1.89
Cash per share	3.99	2.5	2.11	2.79	1.13
Book value per share	11.35	5.89	2.69	3.28	2.35
Tangible book value per share	11.35	5.89	2.69	3.28	2.35
Share holders equity per share	11.35	5.89	2.69	3.28	2.35
Interest debt per share	0.55	1.01	1.35	0.51	0.25
Market cap	7.65M	7.24M	14.83M	10.64M	3.33M
Enterprise value	4.44M	5.02M	13.29M	4.61M	355.12K
P/E ratio	-0.65	-2.46	-3.21	-2.09	-0.65
Price to sales ratio	0.4	0.38	0.8	0.84	0.25
POCF ratio	-0.65	-1.58	-4.39	-2.5	-0.54
PFCF ratio	-0.65	-1.51	-4.17	-2.43	-0.52
P/B Ratio	0.73	0.83	2.77	1.22	0.42
PTB ratio	0.73	0.83	2.77	1.22	0.42
EV to sales	0.23	0.27	0.71	0.37	0.03
Enterprise value over EBITDA	-0.41	-0.83	-3.5	-0.7	-0.08
EV to operating cash flow	-0.38	-1.09	-3.93	-1.09	-0.06
EV to free cash flow	-0.38	-1.05	-3.73	-1.05	-0.06
Earnings yield	-1.54	-0.41	-0.31	-0.48	-1.55
Free cash flow yield	-1.54	-0.66	-0.24	-0.41	-1.93
Debt to equity	0.05	0.17	0.5	0.16	0.11
Debt to assets	0.03	0.1	0.18	0.07	0.05
Net debt to EBITDA	0.3	0.36	0.41	0.92	0.67
Current ratio	3.48	2.55	3.18	2.82	3.71
Interest coverage	-341.15	-416.94	-287.42	588.7	-285.63
Income quality	0.99	1.56	0.86	0.84	1.19
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.98	0	0	0	0
Research and developement to revenue	0.08	0.07	0.03	0.01	0.02
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.04	0.05	0.03	0.04
Capex to revenue	-0.01	-0.01	-0.01	-0.01	-0.02
Capex to depreciation	-0.22	-0.66	-0.79	-0.74	-2.15
Stock based compensation to revenue	0.09	0.04	0.02	0.03	0.05
Graham number	57.11	16.26	11.82	11.89	8.96
ROIC	-1.05	-0.62	-0.46	-0.52	-0.49
Return on tangible assets	-0.82	-0.2	-0.31	-0.27	-0.32
Graham Net	5.16	2	-0.32	0.82	0.53
Working capital	8.91M	7.52M	8.91M	10.61M	10.08M
Tangible asset value	10.49M	8.71M	5.36M	8.7M	7.98M
Net current asset value	8.54M	6.53M	3.36M	6.28M	5.54M
Invested capital	0.05	0.17	0.5	0.16	0.11
Average receivables	2.99M	4.91M	5.01M	4.72M	5.6M
Average payables	1.26M	1.67M	1.93M	1.71M	1.24M
Average inventory	3.14M	2.8M	2.36M	2.6M	2.76M
Days sales outstanding	85.51	103.45	91.23	138.1	176.48
Days payables outstanding	45.4	71.81	53.5	69.36	34.9
Days of inventory on hand	123.32	75.46	76.51	112.56	118.61
Receivables turnover	4.27	3.53	4	2.64	2.07
Payables turnover	8.04	5.08	6.82	5.26	10.46
Inventory turnover	2.96	4.84	4.77	3.24	3.08
ROE	-1.12	-0.34	-0.86	-0.58	-0.65
Capex per share	-0.11	-0.14	-0.09	-0.05	-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q1

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	1.28	1.07	0.95	0.89	0.69
Net income per share	-0.29	-0.33	-0.62	-0.39	-0.29
Operating cash flow per share	-0.49	-0.59	-0.11	-0.72	-0.04
Free cash flow per share	-0.5	-0.6	-0.12	-0.78	-0.05
Cash per share	1.8	1.08	0.85	1.13	0.72
Book value per share	2.57	2.26	1.79	2.35	1.47
Tangible book value per share	2.57	2.26	1.79	2.35	1.47
Share holders equity per share	2.57	2.26	1.79	2.35	1.47
Interest debt per share	0.33	0.25	0.16	0.34	0.13
Market cap	9.05M	6.61M	3.48M	3.33M	5.28M
Enterprise value	4.42M	4.03M	1.33M	355.12K	2.39M
P/E ratio	-2.55	-1.62	-0.45	-0.64	-0.93
Price to sales ratio	2.27	1.98	1.18	1.1	1.54
POCF ratio	-5.91	-3.61	-10	-1.36	-24.57
PFCF ratio	-5.82	-3.56	-9.18	-1.26	-22.77
P/B Ratio	1.14	0.94	0.63	0.42	0.73
PTB ratio	1.14	0.94	0.63	0.42	0.73
EV to sales	1.11	1.21	0.45	0.12	0.7
Enterprise value over EBITDA	-5.37	-5.73	-0.74	-0.32	-2
EV to operating cash flow	-2.88	-2.2	-3.83	-0.15	-11.13
EV to free cash flow	-2.84	-2.17	-3.51	-0.13	-10.31
Earnings yield	-0.1	-0.15	-0.56	-0.39	-0.27
Free cash flow yield	-0.17	-0.28	-0.11	-0.79	-0.04
Debt to equity	0.12	0.11	0.09	0.11	0.09
Debt to assets	0.06	0.05	0.03	0.05	0.04
Net debt to EBITDA	5.62	3.67	1.19	2.67	2.42
Current ratio	3.05	3.51	2.86	3.71	3.36
Interest coverage	-12.76	-243.67	-1.83K	-3.93	0
Income quality	1.73	1.8	0.18	1.87	0.15
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0.07	0.09
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.02	0.01	0.09	0.08	0.08
Capex to revenue	-0.01	-0.01	-0.01	-0.06	0
Capex to depreciation	-0.74	-0.89	-0.97	-5.59	-0.38
Stock based compensation to revenue	0.05	0.03	0.08	0.03	0.05
Graham number	4.06	4.09	5.01	4.51	3.08
ROIC	-0.09	-0.1	-0.29	-0.11	-0.15
Return on tangible assets	-0.05	-0.07	-0.14	-0.08	-0.09
Graham Net	-0.13	-0.39	-0.83	0.53	-0.39
Working capital	9.96M	8.87M	7.3M	10.08M	9.55M
Tangible asset value	7.96M	7.02M	5.56M	7.98M	7.24M
Net current asset value	5.62M	4.45M	2.86M	5.54M	4.94M
Invested capital	0.12	0.11	0.09	0.11	0.09
Average receivables	3.61M	2.46M	2.39M	4.36M	4.43M
Average payables	1.85M	1.57M	1.19M	1.07M	965.5K
Average inventory	2.73M	2.91M	2.94M	2.85M	2.79M
Days sales outstanding	55	67.2	70.22	191.62	64.05
Days payables outstanding	72.97	48.45	55.46	35.2	44.13
Days of inventory on hand	98.9	136.47	121.35	119.64	110.53
Receivables turnover	1.64	1.34	1.28	0.47	1.41
Payables turnover	1.23	1.86	1.62	2.56	2.04
Inventory turnover	0.91	0.66	0.74	0.75	0.81
ROE	-0.11	-0.14	-0.35	-0.16	-0.2
Capex per share	-0.01	-0.01	-0.01	-0.06	0

SNOA Frequently Asked Questions

What is Sonoma Pharmaceuticals, Inc. stock symbol ?

Sonoma Pharmaceuticals, Inc. is a US stock , located in Woodstock of Ga and trading under the symbol SNOA

What is Sonoma Pharmaceuticals, Inc. stock quote today ?

Sonoma Pharmaceuticals, Inc. stock price is $0.777 today.

Is Sonoma Pharmaceuticals, Inc. stock public?

Yes, Sonoma Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 24.3K
Market Capitalization 4.01M
Employee 9
CEO Ms. Amy M. Trombly
Headquarters Woodstock,GA,US
IPO Date 2007-01-25
Website https://www.sonomapharma.com

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.